Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Parallel-Group Phase 1 Study to Investigate the Effect of Various Degrees of Hepatic Impairment on the PK, Safety and Tolerability of the c-Met Kinase Inhibitor Tepotinib

NCT03546608 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT03546608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03546608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Parallel-Group Phase 1 Study to Investigate the Effect of Various Degrees of Hepatic Impairment on the PK, Safety and Tolerability of the c-Met Kinase Inhibitor Tepotinib
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2018
Completion date
February 5, 2019
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment